Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168268 | 0.93 | LTA4H (0.47) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL21168269 | 0.93 | LTA4H (0.47) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL25476856 | 0.84 | ACE (0.37) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL21999092 | 0.84 | FKBP1A (0.48) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL25476847 | 0.83 | F2 (0.36) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL25476858 | 0.82 | DPP4 (0.34) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL24058760 | 0.79 | REN (0.39) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL25476871 | 0.78 | F2 (0.39) | F2ALDH1A1FKBP1AACE | |
| SCHEMBL24058544 | 0.78 | ACE (0.37) | CYP3A4CYP2C9PKMCYP2C19F2 | |
| SCHEMBL24058502 | 0.78 | ACE (0.37) | CYP3A4CYP2C9PKMCYP2C19F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | CYP3A4 4726/4885CYP2C9 4797/4885PKM 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.